news
Two children died from gene therapies in China
Chinese officials reported two children died during gene therapy trials for spinal muscular atrophy. This is the first public acknowledgement of deaths in gene therapy trials in China, raising questions about oversight and safety in the rapidly expanding biotech field.
Chinese officials reported two children died during gene therapy trials for spinal muscular atrophy. This is the first public acknowledgement of deaths in gene therapy trials in China, raising questions about oversight and safety in the rapidly expanding biotech field.
The architecture take
This isn't just about tragic patient outcomes; it's a cold splash of reality for a biotech sector that sometimes feels like the Wild West. Gene therapies promise to rewrite the body's code, but the risks are still massive, especially when regulatory bodies aren't as transparent or robust as they could be. I'm watching this for what it means for how clinical trials are run globally, and how much data regulators are actually sharing. When the stakes are this high — literally life and death — the mechanisms for ensuring patient safety need to be ironclad, not just in theory. Your body, your cells, should never be a game of chance. This news will likely trigger a much-needed re-evaluation of ethical guidelines and monitoring practices, not just in China but across the board.